#ICYMI : Left Main Revascularization in Diabetes #AHAJournals Prakriti Gaba Brian Bergmark TIMI Study Group

Join us for our session, 'Diabetes and CVD' with our renowned speakers at the 8th Heart in Diabetes!

Earn #CME credits and register now at heartindiabetes.com/registration

Liz Selvin David Berg @JohnHopkinsSPH Duke Clinical Research Institute Brigham and Women's Hospital Harvard Medical School TIMI Study Group American Heart Association #HID24

Clinical Highlights From the American College of Cardiology’s 2024 Scientific Session, including the Bridge-TIMI 73a trial in JAMA Cardiology Brian Bergmark Nicholas Marston
jamanetwork.com/journals/jama/…

Bridge-TIMI 73a primary results featured in NEJM Journal Watch Brian Bergmark Nicholas Marston #olezarsen
jwatch.org/na57300/2024/0…

Coverage in Healio of Bridge-TIMI 73a results @brianbergmark Nicholas Marston #olezarsen
healio.com/news/cardiolog…

Bridge-TIMI 73a results coverage in PACE-CME @brianbergmark Nicholas Marston
pace-cme.org/congress-cover…

Coverage in Medscape of Brian Bergmark's #ACC24 LBCT presentation of the Bridge-TIMI 73a results. Robert Giugliano Nicholas Marston
medscape.com/viewarticle/ea…

In this issue of Circulation-“Summarizing Primary Results in Clinical Trials with a Time-to-event Endpoint.” This is the first of a series of statistical review articles for cardiologists from Andrea Bellavia and Sabina Murphy, to be published quarterly. ahajournals.org/doi/10.1161/CI…

#CircACC24 #SimPub SGLT2i Trialists Consortium: primary benefit of SGLT2i for MACE driven by reduction in CV death, without clear effect on myocardial infarction or stroke Sid M. Patel TIMI Study Group #AHAJournals ahajournals.org/doi/10.1161/CI…

Sim Pub w/ #ACC24 in #CircHF by Sid M. Patel et al: Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights from the CCCTN Registry
ahajournals.org/doi/10.1161/CI… #AHAJournals AHA Science Nancy Sweitzer MDPhD Sid M. Patel
TIMI Study Group

Elderly pts with ASCVD derive similar to greater CV benefit compared to younger pts with early initiation of #evolocumab up to 8.6 yrs with no significant safety concerns. These findings may be helpful in guiding future US recommendations. Samer Alsaid Robert Giugliano #ACC24

Next up at #ACC24 : Brian Bergmark reported that olezarsen by Ionis was linked to consistent TG reductions among patients with high-risk hypertriglyceridemia compared to a placebo. There were no major safety concerns.

More data on the drug will be presented later today.

.Brian Bergmark shares the breakthroughs in BRIDGE-TIMI 73a

#ESCTVOnTheRoad #ACC24

Dr. Brian Bergmark on the BRIDGE – TIMI 73a at the #ACC24 LBCT II press conference added that olezarsen significantly reduced triglyceride levels and the effect is greater than what is possible with currently available treatments.

🎙️NEW #ACC24 #LBCT Interview 💫Dr Brian Bergmark joins us to discuss findings from a study into #olezarsen in adults with hypertriglyceridemia and #ASCVD .

📽️Watch here👉 tinyurl.com/dxjpr2ee

📊50mg or 80mg olezarsen monthly significantly reduced triglyceride levels in

Phase 2b trial results of olezarsen, an anti-sense oligonucleotide inhibiting ApoC3, demonstrating its efficacy and safety among patients with moderate hypertriglyceridemia. Stay tuned for the ongoing phase 3 trial on olezarsen! TIMI Study Group Brian Bergmark

Monthly #olezarsen reduced #triglyceride levels vs. placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk Brian Bergmark Dan Soffer American College of Cardiology #Cardiotwitter #ACC24 Endocrine Today Healio

Read more👇
healio.com/news/cardiolog…

“The triglyceride effect was greater than is possible with currently available treatments,” Brian Bergmark Dan Soffer American College of Cardiology #Cardiotwitter #ACC24 Endocrine Today Healio

Read more👇
healio.com/news/cardiolog…

According to research presented at #ACC24 , olezarsen cuts triglyceride levels by about half. The study’s lead author Dr. Brian Bergmark discussed the findings with a reporter for CVGK.

“The triglyceride effect was greater than is possible with currently available treatments,” Brian Bergmark Dan Soffer American College of Cardiology #Cardiotwitter #ACC24 Endocrine Today Healio

Read more👇
healio.com/news/cardiolog…